Most recently, Dr Rioux was chief medical officer (CMO) of FerroKin Biosciences, a developer of iron chelator for treatment of anemias. Prior to that, Dr Rioux was CMO and vice president of clinical and regulatory for Edison Pharmaceutical.
Christopher Starr, CEO of Raptor, said: “As a clinical-stage company with multiple active programs, we are pleased to welcome Dr Rioux. This is an ideal time for Patrice to join Raptor. We believe his successful clinical and regulatory track record will serve us well as we prepare for a pivotal clinical trial in our lead clinical program, DR Cysteamine in cystinosis, and position us to advance our other clinical-stage programs through the clinic and into the market.”